Bristol-Myers Squibb Co (BMY) : Hyman Charles D reduced its stake in Bristol-Myers Squibb Co by 1.68% during the most recent quarter end. The investment management company now holds a total of 198,551 shares of Bristol-Myers Squibb Co which is valued at $14,140,802 after selling 3,400 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on May 3, 2016.Bristol-Myers Squibb Co makes up approximately 2.22% of Hyman Charles D’s portfolio.
Other Hedge Funds, Including , Jennison Associates reduced its stake in BMY by selling 774,930 shares or 2.79% in the most recent quarter. The Hedge Fund company now holds 26,964,930 shares of BMY which is valued at $1,920,442,315. Bristol-Myers Squibb Co makes up approx 2.03% of Jennison Associates’s portfolio.Braun Stacey Associates Inc reduced its stake in BMY by selling 42,691 shares or 13.26% in the most recent quarter. The Hedge Fund company now holds 279,179 shares of BMY which is valued at $19,883,128. Bristol-Myers Squibb Co makes up approx 1.29% of Braun Stacey Associates Inc’s portfolio.Kornitzer Capital Management Inc Ks boosted its stake in BMY in the latest quarter, The investment management firm added 49,675 additional shares and now holds a total of 59,050 shares of Bristol-Myers Squibb Co which is valued at $4,205,541. Bristol-Myers Squibb Co makes up approx 0.08% of Kornitzer Capital Management Inc Ks’s portfolio. Moisand Fitzgerald Tamayo sold out all of its stake in BMY during the most recent quarter. The investment firm sold 90 shares of BMY which is valued $6,496.Reilly Financial Advisors boosted its stake in BMY in the latest quarter, The investment management firm added 298 additional shares and now holds a total of 15,987 shares of Bristol-Myers Squibb Co which is valued at $1,129,961. Bristol-Myers Squibb Co makes up approx 0.25% of Reilly Financial Advisors’s portfolio.
Bristol-Myers Squibb Co opened for trading at $71.75 and hit $71.75 on the upside on Tuesday, eventually ending the session at $71.53, with a gain of 0.27% or 0.19 points. The heightened volatility saw the trading volume jump to 57,58,820 shares. Company has a market cap of $119,406 M.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.65. The company had revenue of $4391.00 million for the quarter, compared to analysts expectations of $4268.65 million. The company’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.71 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Company shares were Reiterated by UBS on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 80 from a previous price target of $73 .Company shares were Reiterated by Barclays on Apr 29, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 75 from a previous price target of $70 .Societe Generale Initiated Bristol-Myers Squibb Co on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $48.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.